Výsledky vyhledávání

Outcomes of BRAF, MET, RET, and ROS1 Mutated Non-Small Cell Lung Cancer With Brain Metastases (NSCLCBM)

Autor: David M. Peereboom, John H. Suh, Erin S. Murphy, Yasmeen Rauf, Samuel T. Chao, Manmeet S Ahluwalia, Patrick Joseph O'Shea, Xuefei Jia, V. Tatineni

Publikováno v: International Journal of Radiation Oncology*Biology*Physics. 111:e582-e583

Purpose/Objective(s) Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) also accounts for the highest number of brain metastases. Recent advances have been made from standard platinum-based chemoth

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0941e3fb2aeee32afd1f06031fa7da58
https://doi.org/10.1016/j.ijrobp.2021.07.1563

Zobrazit plný text záznamu

Comparison of the efficacy of venous coupler and hand-sewn anastomosis in maxillofacial reconstruction using microvascular fibula free flaps: a prospective randomized controlled trial

Autor: K. Mohammed Afradh, M. Senthil Murugan, Poornima Ravi, V. Tatineni, V.B. Krishnakumar Raja

Publikováno v: International Journal of Oral and Maxillofacial Surgery. 47:854-857

The venous coupler has emerged as a suitable alternative to hand suturing in the microvascular anastomosis of blood vessels; however, no prospective comparative studies have been performed to date. The aim of this study was to prospectively compare t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0896091c62df1b60e979ddf7af3dd955
https://doi.org/10.1016/j.ijom.2018.01.016

Zobrazit plný text záznamu

Outcomes of BRAF Mutated vs. Wild Type Tumors in Melanoma Brain Metastasis

Autor: Patrick Joseph O'Shea, Xuefei Jia, Yasmeen Rauf, David M. Peereboom, V. Tatineni, Manmeet S Ahluwalia, John H. Suh, Erin S. Murphy, Samuel T. Chao

Publikováno v: International Journal of Radiation Oncology*Biology*Physics. 111:e576

Purpose/Objective(s) Melanoma is the third most common cause of metastatic brain tumors. A mutation of the BRAF protein, a kinase implicated in cell differentiation and growth, is present in approximately 50% of patients with melanoma. BRAF inhibitor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::477c2522b55cfef2e1e9ed33f127320e
https://doi.org/10.1016/j.ijrobp.2021.07.1551

Zobrazit plný text záznamu

Outcomes of immunotherapy (ICI) alone vs tyrosine kinase inhibitors (TKI) alone versus ICI and TKI combined in renal cell carcinoma brain metastasis

Autor: Erin S. Murphy, V. Tatineni, Yasmeen Rauf, David M. Peereboom, Xuefei Jia, John H. Suh, Patrick Joseph O'Shea, Samuel T. Chao, Manmeet Ahluwalia

Publikováno v: Journal of Clinical Oncology. 39:2030-2030

2030 Background: Renal cancer is the fourth most common cause of metastatic tumors to the brain. Tyrosine kinase inhibitors (TKIs) targeting VEGFR and other receptors, such as sunitinib, pazopanib, etc., have been used as first line for renal cell ca

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::508c5d67ea7a28b0397f8bc5ff7009af
https://doi.org/10.1200/jco.2021.39.15_suppl.2030

Zobrazit plný text záznamu

Outcomes of first-generation versus third-generation epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer with brain metastases (NSCLCBM)

Autor: Yasmeen Rauf, Samuel T. Chao, Manmeet Ahluwalia, David M. Peereboom, Patrick Joseph O'Shea, Erin S. Murphy, V. Tatineni, Xuefei Jia, John H. Suh

Publikováno v: Journal of Clinical Oncology. 39:2031-2031

2031 Background: Non-small cell lung cancer (NSCLC) is the most common cause of brain metastases, with 10-30% of patients developing brain metastases. EGFR is a transmembrane glycoprotein that is mutated in up to 50% of NSCLCs. First-generation EGFR

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7353befb59c70feebbcc16423094b8ba
https://doi.org/10.1200/jco.2021.39.15_suppl.2031

Zobrazit plný text záznamu

Outcomes of first, second, and third-generation anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer brain metastases (NSCLCBM)

Autor: Manmeet Ahluwalia, Erin S. Murphy, David M. Peereboom, Patrick Joseph O'Shea, Yasmeen Rauf, Samuel T. Chao, John H. Suh, V. Tatineni, Xuefei Jia

Publikováno v: Journal of Clinical Oncology. 39:2034-2034

2034 Background: Non-small cell lung cancer (NSCLC) is the most common cause of brain metastases. ALK, which codes for tyrosine kinase receptors, is rearranged in 4-7% of NSCLC. First-generation ALK inhibitors have restricted efficacy due to poor blo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::258601f65fbb2aeb70433a2dd4980d36
https://doi.org/10.1200/jco.2021.39.15_suppl.2034

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání